DrugBiological
Mavrilimumab clinical trials
Also written KPL-301 and CAM-3001.
- studies test it
- 12
- open now
- 0
- in phase 3
- 1
- first study started
- 2008
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2020 (5)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2018 | 1 |
| 2020 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 10
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 4
MedImmune LLC (5) · Kiniksa Pharmaceuticals International, plc (1) · Kristin Hudock (1) · Kiniksa Pharmaceuticals, Ltd. (1) · Virginia Commonwealth University (1) · The Cleveland Clinic (1) · MedImmune Ltd (1) · Ospedale San Raffaele (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses mavrilimumab is read from its arms, and is right about nine times in ten.
Testing it · 12
- Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammationCompletedPhase 2/3Kiniksa Pharmaceuticals International, plcNCT04447469Written as mavrilimumab
- Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammationCompletedPhase 2Kristin HudockNCT04492514Written as Mavrilimumab
- KPL-301 for Subjects With Giant Cell ArteritisCompletedPhase 2Kiniksa Pharmaceuticals, Ltd.NCT03827018Written as mavrilimumab
- Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammationCompletedPhase 2Virginia Commonwealth UniversityNCT04463004Written as Mavrilimumab
- Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammationCompletedPhase 2The Cleveland ClinicNCT04399980Written as Mavrilimumab
- Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19)Status unknownPhase 2Ospedale San RaffaeleNCT04397497Written as Mavrilimumab
- A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid ArthritisCompletedPhase 2MedImmune LLCNCT01050998Written as Mavrilimumab 10 mg
- A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid ArthritisTerminatedPhase 2MedImmune LLCNCT01712399Written as Mavrilimumab 100 mg
- A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid ArthritisCompletedPhase 2MedImmune LLCNCT01715896Written as Mavrilimumab 100 mg
- A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid ArthritisCompletedPhase 2MedImmune LLCNCT01706926Written as Mavrilimumab 30 mg
- A Double-blind, Placebo-controlled, Single-dose Study to Evaluate the PK, IM, and Safety in Japanese SubjectsCompletedPhase 1MedImmune LLCNCT02213315Written as 100mg Mavrilimumab
- A Single Dose Study of the CAM-3001 in Patients With Rheumatoid ArthritisCompletedPhase 1MedImmune LtdNCT00771420Written as CAM-3001
Codes
What other systems call mavrilimumab · ClinicalTrials.gg INT005902
- MeSH (NLM) C561644mavrilimumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 1158JD1P9AMAVRILIMUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q6794291mavrilimumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95788MavrilimumabOne source FDA
- DrugBank DB12534One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C561644 | mavrilimumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 1158JD1P9A | MAVRILIMUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q6794291 | mavrilimumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95788 | Mavrilimumab | One source FDA |
| DrugBank | DB12534 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.